<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87470">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02072551</url>
  </required_header>
  <id_info>
    <org_study_id>GLUCONEO</org_study_id>
    <nct_id>NCT02072551</nct_id>
  </id_info>
  <brief_title>Future of Beta Cells in Adults With Genetic Abnormality Behind Neonatal Diabetes</brief_title>
  <acronym>GLUCONEO</acronym>
  <official_title>Devenir au Long Cours de la Cellule bêta Chez Les Adultes Porteurs d'Anomalies génétiques à l'Origine du Diabète Néonatal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate Beta cells in patients with a neonotal
      diabetes linked to a genetic abnormality Metabolic caracteristics will described using a
      transversal cohort study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Mean insulin secretion output</measure>
    <time_frame>Week after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin secretion outout after arginine perfusion</measure>
    <time_frame>during hospitalisation (3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sensitivity to insulin</measure>
    <time_frame>during hospitalisation (3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucago secretion output</measure>
    <time_frame>during hospitalisation (3 days)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Adult with neonatal diabetes</arm_group_label>
    <description>Adult with neonatal diabetes (before 1 year ) and need for insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non diabetic adults with a relative with neonatal diabetes</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        diabetic people
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age : 18 à 65 year

          -  diabetic patient with a neonatal diabetis (before 1 year old) and need for insuline
             or patient with a relative having neonatal diabetis

        Exclusion Criteria:

        Diabète induit (médicaments - ex corticoïdes) ou syndromique

          -  infection

          -  cancer

          -  pegnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-François GAUTIER, MD PhD</last_name>
    <phone>+33 1 42 49 96 87</phone>
    <email>jean-françois.gautier@sls.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Siant-louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François GAUTIER, MD PHD</last_name>
      <phone>+33 1 42 49 96 87</phone>
      <email>jean-françois.gautier@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François GAUTIER, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
